Promising Alzheimer's Drug Slows Disease Progression, Offers Hope

Eli Lilly has released trial results showing that its new drug, donanemab, significantly slows memory loss and cognitive decline in Alzheimer's patients. The phase 3 clinical study demonstrated a 35% reduction in disease progression in the early stages. The drug, based on antibodies against amyloid, has been submitted for FDA approval, with a decision expected by the end of the year. Dementia experts have hailed this as a landmark moment in Alzheimer's treatment, following similar findings for another antibody drug, lecanemab. Future therapies are expected to be tailored drug combinations based on individual biomarker tests.